Medicenna Therapeutics Corp

No Longer Reporting

The company has not filed an annual or quarterly report since its FY2023 20-F, filed Jun 27, 2023. Its latest SEC filing is a D from Jul 6, 2026.

The sections below describe the company as of the FY2023 annual report.

What Did They Do?

Develops engineered cytokine treatments and fused immunotherapies for cancer and other diseases.

Who Did They Compete With?

Competes with Alkermes, Sanofi, Cue Biopharma, Mabwell, Avenge Bio, Anaveon, Selecxine, BioNTech, Xilio Therapeutics, Ascendis Pharma, Aulos, Asher Bio, Synthekine, Jiangsu HengRui Medicine, and Werewolf